In vitroandin vivopharmacological profile of UFP‐512, a novel selective δ‐opioid receptor agonist; correlations between desensitization and tolerance
Open Access
- 1 December 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (8) , 1312-1324
Abstract
Background and purpose: δ‐Opioid receptors (DOP receptors) could represent a novel target in the treatment of depressive disorders. To explore this new field of interest, the development of highly selective DOP receptor agonists is essential. UFP‐512 [H‐Dmt‐Tic‐NH‐CH(CH2‐COOH)‐Bid], was recently shown to behavein vitroas a selective and potent DOP receptor agonist and to promote antidepressant‐ and anxiolytic‐like effectsin vivo(Verguraet al., 2007). Here, we have characterized the pharmacological properties of UFP‐512 and established a link between desensitization and tolerance.Experimental approach: Studies were performed in the human neuroblastoma SK‐N‐BE cells to establish i) binding parameters for UFP‐512 ii) signalling pathways activated after acute and chronic treatment iii) regulation (phosphorylation and trafficking) of human DOP (hDOP) receptors after sustained activation by UFP‐512.In vivo, we studied UFP‐512‐induced antidepressant‐like effects after acute or chronic treatment in the mouse forced swimming test.Key results: In vitro, UFP‐512 was a high affinity agonist for DOP receptors. While UFP‐512 induced marked phosphorylation of DOP receptors on Ser363, we observed a low desensitization of the cAMP pathway, associated with receptor endocytosis and recycling without any reduction on extracellular signal‐regulated protein kinase 1/2 activation.In vivo, acute administration of UFP‐512 produced an antidepressant‐like effect, without any sign of tolerance after chronic administration.Conclusions and implications: There was a correlation between weak desensitization, significant internalization and recycling of the human DOP receptors and lack of tolerance to UFP‐512. This suggests that this compound would be a promising drug prototype for exploring innovative treatments for mood disorders.British Journal of Pharmacology(2007)152, 1312–1324; doi:10.1038/sj.bjp.0707497; published online 5 November 2007Keywords
This publication has 37 references indexed in Scilit:
- Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of EfficacyMolecular Pharmacology, 2006
- The Antidepressant -like Effects of Delta-Opioid Receptor AgonistsMolecular Interventions, 2006
- Tracking the opioid receptors on the way of desensitizationCellular Signalling, 2006
- Morphine Promotes Rapid, Arrestin-Dependent Endocytosis of μ-Opioid Receptors in Striatal NeuronsJournal of Neuroscience, 2005
- Different Regulation of Human δ-Opioid Receptors by SNC-80 [(+)-4-[(αR)-α-((2 S,5 R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Endogenous EnkephalinsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Differential Sorting of Human δ-Opioid Receptors after Internalization by Peptide and Alkaloid AgonistsJournal of Biological Chemistry, 2003
- Desensitization of the δ‐Opioid Receptor Correlates with Its Phosphorylation in SK‐N‐BE Cells: Involvement of a G Protein‐Coupled Receptor KinaseJournal of Neurochemistry, 1998
- The δ‐Opioid Receptor in SK‐N‐BE Human Neuroblastoma Cell Line Undergoes Heterologous DesensitizationJournal of Neurochemistry, 1997
- The δ‐Opioid Receptor Regulates Activity of Ryanodine Receptors in the Human Neuroblastoma Cell Line SK‐N‐BEJournal of Neurochemistry, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973